Bevacizumab biosimilar (Hetero Drugs)

贝伐珠单抗生物类似药（Hetero Drugs）

Report date: 2022/03/14 15:25:54

Base Information

Drug NameBevacizumab biosimilar (Hetero Drugs)

Drug Alias Name贝伐珠单抗生物仿制药（Hetero Drugs）Bevacizumabum (Hetero Drugs)Bevacizumab (Hetero Drugs)贝伐赛珠单抗生物仿制药（Hetero Drugs）贝伐单抗生物仿制药（Hetero Drugs） +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsColorectal Neoplasms

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2016/06/27

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesHetero Drugs Ltd

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsColorectal Neoplasms

Inactive IndicationsN/A

ATC CodeL01XC07